Is 10x Genomics (TXG) Fully Priced On Its New Lunit AI Pathology Partnership?

10x Genomics (TXG) is back in focus after Lunit agreed to plug its AI pathology engine into 10x's oncology biomarker discovery workflow, linking image analysis with spatial molecular readouts.

The fresh AI partnership arrives after a sharp run in 10x Genomics’ shares, with a 30-day share price return of 32.63% and a 90-day move of 131.53%. The year-to-date share price return of 347.59% and 1-year total shareholder return of 466.57% signal very strong momentum building behind the story.

Spot 39 healthcare AI stocks already attracting attention from investors watching how 10x Genomics is leaning into AI-powered oncology research.

After a move that has taken 10x Genomics far above the average analyst target and well past many intrinsic value estimates, the question now is whether investors are overpaying or analysts are behind the curve.

Most Popular Narrative: 50% Overvalued

At a last close of $74.39 against a narrative fair value of $49.54, 10x Genomics is framed as richly priced, with the widely followed storyline hinging on how much AI driven demand and platform expansion can justify that gap.

Recent and upcoming product launches, including Flex v2 (targeting higher throughput, lower costs, and AI integration), Visium HD extensions, and Xenium RNA plus protein, are expanding the range of applications and reinforcing 10x's leadership in advanced genomics tools, expected to drive both top-line growth and sustain premium pricing over time.

See why 28 investors see 10x Genomics as 50% overvalued.

Result: Fair Value of $49.54 (OVERVALUED)

Still, funding pressure on academic buyers and lower instrument pricing could easily cool demand, which would challenge the upbeat 10x Genomics narrative.

Find out about the key risks to this 10x Genomics narrative.

Next Steps

If this mix of optimism and concern around 10x Genomics feels familiar, do not wait on others to decide the story for you. Consider both the potential benefits and the possible risks by reviewing the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond 10x Genomics?

Do not let the 10x Genomics story be the only place you look. Broaden your watchlist with other ideas that match your style and risk comfort.

• Target potential bargains trading below estimated worth by scanning our 34 high quality undervalued stocks and compare them with what you see in TXG today.
• Build a steadier income-focused portfolio by reviewing the 6 dividend fortresses that could complement higher volatility holdings like 10x Genomics.
• Protect your downside by filtering for stability using the 11 resilient stocks with low risk scores before momentum cools or conditions shift around TXG.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com